Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ...
Early detection and innovative therapies are crucial for managing rare blood disorders like VITT, ITP, and hemophilia. Marstacimab's approval offers a new subcutaneous treatment option for hemophilia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback